Shire plc: Core Portfolio of Products Delivers 20% Sa...( DUBLIN August 5 /- - 2009 ...)

DUBLIN, August 5 /PRNewswire-FirstCall/ --

- 2009 Guidance Framework Reaffirmed

Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to June 30, 2009.

    Q2 2009 Financial Highlights

                                                             Q2 2009(1)

    Product sales                                  $558 million        -21%

    Product sales (excluding ADDERALL XR)          $491 million        +20%
    Product sales growth (excluding ADDERALL XR) at
    constant exchange rates(2)                                         +27%

    Non GAAP operating income                      $116 million        -53%

    US GAAP operating income                        $35 million +$102 million
    Non GAAP diluted earnings per ADS (using actual Q2
    2009 tax rate: 2%)                                    $0.60        -36%
    Non GAAP diluted earnings per ADS (using full year
    expected tax rate: 24%)                               $0.47
    US GAAP diluted earnings per ADS                      $0.24     +$0.68


    (1) Figures compare Q2 2009 results with the same period in 2008.

(2) Sales growth at constant exchange rates ("CER"), which is a Non GAAP measure, is calculated after restating Q2 2009 results using Q2 2008 average foreign exchange rates.

Angus Russell, Chief Executive Officer, commented:

"In the second quarter we delivered strong core product sales, excluding ADDERALL XR, of $491 million, representing growth of 20% compared to the same quarter last year. The strategic steps we have taken over the last few years are now delivering clear commercial benefits, as we enter a new phase of Shire's development.

We have diversified into a broader portfolio of young pro
'/>"/>